Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

Pfizer's $90b Lipitor Vs LL: The largest buy-ou

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 154287
(Total Views: 707)
Posted On: 05/31/2025 12:43:13 AM
Posted By: My69z
Pfizer's $90b Lipitor Vs LL:

The largest buy-out in pharma history by Pfizer.
Why ? For full iP rights.
___
*Pfizer started a hostile takeover of Warner-Lambert in December 1999. One of the principle reasons being to secure the full rights to Warner-Lambert's Lipitor (atorvastatin), which Pfizer already co-promoted with Warner-Lambert.
___
Can, not, overlook our patent value.

Ladies of Leronlimab have validated our iP as an Exclusive & Non-exclusive Right(s).

Even exclusive mfgr'ing rights = serious profits.

In 2000, Pfizer paid $90b for Warner-Lambert to fully gain the remaining 11 yrs of patent rights out to 2011.

The two had actually co-marketed Lipitor.

Lipitor of course has SAE's & drug-drug interactions, with the YOY sales & total market projections are puny, i mean puny in comparison to just our oncology focus.
___
*Atorvastatin, marketed as Lipitor, was a blockbuster drug, peaking at almost $13 billion in sales in 2006. While sales have declined since the patent expired in 2011, with most sales now coming from emerging markets like China, Lipitor still generates roughly $2 billion per year. The global atorvastatin market is estimated to be around US$4.6 billion in 2024 and is projected to grow to US$6.05 billion by 2031.

*Atorvastatin belongs to a class of drugs called statins or HMG-CoA reductase inhibitors.

It works by inhibiting an enzyme in the liver that's crucial for cholesterol production.

By reducing cholesterol production and increasing the liver's ability to remove LDL cholesterol, Atorvastatin helps lower LDL ("bad" cholesterol and triglycerides, while also slightly increasing HDL ("good" cholesterol.
___
For me,
a buy-out if only VERY north of $90b @ largest ever in the pharma industry.

Or...we build a Leronlimab j/v empire unlike no other.


(3)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us